To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Compare the Effects of 12 Weeks Treatment With Vildagliptin 50 mg Bid to Voglibose 0.2 mg Tid in Patients With Type 2 Diabetes

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00368134

Enrollment

370

Registered

2006-08-24

Start date

2006-08-31

Completion date

Unknown

Last updated

2007-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Type 2 Diabetes, Vildagliptin, HbA1c

Brief summary

This study is designed to evaluate the efficacy, safety and tolerability of vildagliptin compared to voglibose in patients with type 2 diabetes. Please note this study is not being conducted in the United States.

Interventions

DRUGVildagliptin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Inclusion criteria

* Diagnosis as Type 2 Diabetes * Patients who have been placed on dietary therapy/exercise therapy, without achievement of glycemic control * Outpatients

Exclusion criteria

* Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes * Significant heart diseases * Significant diabetic complications Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Change in HbA1c after 12 weeks	—

Secondary

Measure	Time frame
Change in FPG after 12 weeks	—
Change in Fasting Lipids after 12 weeks	—
Change in HOMA-IR after 12 weeks	—
Change in HOMA-B after 12 weeks	—
Safety Profile after 12 weeks treatment	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026